DA-1241 是一种具有口服活性的 GPR119 激活剂和 NF-κB 抑制剂,对人、小鼠、大鼠、仓鼠 GPR119 的 EC50 分别为 4.37 nM、71.5 nM、156 nM 和 14.7 nM,对 NF-κB 的 IC50 为 84.2 nM;它通过激活 GPR119 刺激肠道 GLP-1 分泌、诱导自噬 (autophagy) 降解脂滴并抑制肝脏糖异生来发挥降糖作用,通过抑制 NF-κB 通路的激活减少巨噬细胞分化和促炎因子的释放并抑制细胞凋亡 (apoptosis) 以保护肝脏功能,还通过抑制 ER 应激和维持 PDX1 表达来保护 β 细胞功能,可用于代谢功能障碍相关脂肪性肝炎、2 型糖尿病和非酒精性脂肪性肝病的研究。
产品编号: MS-R24593 纯度: 99.18% CAS No.: 1914136-10-9 分子式: C25H31F2N5O2 分子量: 471.54
MolStrong 的所有产品仅用作科学研究或药证申报,我们不为任何个人用途提供产品和服务
规格 价格 是否有货 数量 购物车
10mM * 1mL in DMSO
询价
3-5 天
5mg
询价
3-5 天
10mg
询价
3-5 天
25mg
询价
3-5 天
50mg
询价
询价
100mg
询价
询价
200mg
询价
询价
500mg
询价
询价

产品描述

DA-1241 是一种具有口服活性的 GPR119 激活剂和 NF-κB 抑制剂,对人、小鼠、大鼠、仓鼠 GPR119 的 EC50 分别为 4.37 nM、71.5 nM、156 nM 和 14.7 nM,对 NF-κB 的 IC50 为 84.2 nM;它通过激活 GPR119 刺激肠道 GLP-1 分泌、诱导自噬 (autophagy) 降解脂滴并抑制肝脏糖异生来发挥降糖作用,通过抑制 NF-κB 通路的激活减少巨噬细胞分化和促炎因子的释放并抑制细胞凋亡 (apoptosis) 以保护肝脏功能,还通过抑制 ER 应激和维持 PDX1 表达来保护 β 细胞功能,可用于代谢功能障碍相关脂肪性肝炎、2 型糖尿病和非酒精性脂肪性肝病的研究。

生物实验数据

生物活性 DA-1241 is an orally active GPR119 agonist and NF-κB inhibitor with EC50 values of 4.37 nM, 71.5 nM, 156 nM, and 14.7 nM for human, mouse, rat, and hamster GPR119, respectively, and an IC50 of 84.2 nM for NF-κB; it exerts glucose-lowering effects by activating GPR119 to stimulate intestinal GLP-1 secretion, induce autophagy-mediated degradation of lipid droplets, and inhibit hepatic gluconeogenesis, protects liver function by inhibiting activation of the NF-κB pathway to reduce macrophage differentiation and the release of pro-inflammatory cytokines and to suppress apoptosis (apoptosis), and protects β-cell function by inhibiting ER stress and maintaining PDX1 expression, and can be used for research on metabolic dysfunction-associated steatohepatitis, type 2 diabetes, and non-alcoholic fatty liver disease.
IC50 & Target

NF-κB

84.2 nM (IC50)

体外研究
(In Vitro)

DA-1241 (10 μM;4 h) 可抑制 TNFα 诱导的人肝癌细胞 HepG2 中 NFκB p65 的核转位。
DA-1241 (10 μM;48 h) 可减弱 LPS (MS-X54539) 诱导的 NF-κB 通路激活、炎症小体组分上调,以及人 THP-1 巨噬细胞中促炎细胞因子 (IL-1β、TNFα) 的分泌。
DA-1241 (1000 nM; 24 h) 可降低饥饿状态下 HepG2 细胞中糖异生酶 G6Pase 和 PEPCK 的表达。
DA-1241 (1000 nM; 24 h) 可调控自噬流标志物,在饥饿的 HepG2 细胞中促进 LC3-I 向 LC3-II 的转化并上调 p62 蛋白表达。
DA-1241 (1000 nM; 24 h) 可降低经饥饿处理、转染 mRFP-GFP-LC3 的 HepG2 细胞中的自噬流,表现为黄色 LC3 斑点增加、红色 LC3 斑点减少。
DA-1241 (100 μM; 18 h) 以依赖 GPR119 的方式在 Hep3B 细胞和 GFP-TFEB HeLa 细胞中诱导自噬、TFEB 核转位、cAMP 升高并减少脂质积累,而 GPR119 敲低可消除这些作用。
DA-1241 (0.01 nM-10 μM;1 h) 可强效提升 HIT-T15 仓鼠胰岛素瘤细胞内的 cAMP 水平,其 EC50 为 14.7 nM。
DA-1241 (0.01-100 μM;30 min) 可强效刺激 HIT-T15 仓鼠胰岛素瘤细胞中葡萄糖依赖性的胰岛素分泌,其 EC50 为 22.3 nM。
DA-1241 (0.1-1 μM;8 h) 可显著抑制毒胡萝卜素诱导的 HIT-T15 仓鼠胰岛素瘤细胞凋亡,使凋亡率降至接近对照组水平。
DA-1241 (0.1-10 μM) 可浓度依赖性地抑制毒胡萝卜素诱导的 HIT-T15 仓鼠胰岛素瘤细胞中内质网应激标记基因 BiP 和 CHOP 的表达,在 10 μM 浓度下抑制作用显著。
DA-1241 (1-10 μM; 6 h) 可抑制毒胡萝卜素诱导的 JNK、ERK1/2 和 p38 MAPK 活化,并降低 HIT-T15 仓鼠胰岛素瘤细胞中内质网应激标志物 BiP 和 CHOP 的蛋白表达。
DA-1241 (0.1 μM;6 h) 对毒胡萝卜素诱导的 HIT-T15 仓鼠胰岛素瘤细胞内质网应激具有保护作用,该作用依赖于 GPR119 的激活,因为敲低 GPR119 可消除 DA-1241 的活力挽救效应。

Immunofluorescence

Cell Line: human HepG2 hepatoma cells
Concentration: 10 μM
Incubation Time: 4 h (pre-incubation); 0.5 h (TNFα stimulation)
Result: Prevented TNFα-induced nuclear translocation of the NFκB p65 subunit, retaining p65 in the cytosol instead of allowing it to accumulate in the nucleus.

ELISA Assay

Cell Line: parental and GPR119 KO human THP-1 macrophages
Concentration: 0, 0.3, 1, 3, 10 μM
Incubation Time: 48 h (PMA-induced differentiation); 4 h (LPS stimulation)
Result: Inhibited LPS-induced TNFα secretion in a concentration-dependent manner in parental THP-1 macrophages.
Had no effect on LPS-induced TNFα secretion in GPR119 KO THP-1 macrophages at any tested concentration.

Western Blot Analysis

Cell Line: human hepatocellular carcinoma HepG2 cells
Concentration: 1000 nM
Incubation Time: 24 h (with bafilomycin A1 added for final 2 h)
Result: Increased LC3-I to LC3-II conversion, an effect augmented by bafilomycin A1 co-treatment, and increased protein expression of p62.

Immunofluorescence

Cell Line: human hepatocellular carcinoma HepG2 cells (mRFP-GFP-LC3-transfected)
Concentration: 1000 nM
Incubation Time: 24 h (with bafilomycin A1 added for final 2 h)
Result: Increased the number of yellow LC3-GFP puncta and decreased the number of red mRFP puncta, and reduced the mRFP/GFP-LC3 ratio, indicating reduced autophagic flux.

Cell Viability Assay

Cell Line: HIT-T15 hamster insulinoma cells
Concentration: 0.001-10 μM (co-treated with 0.3 μM thapsigargin)
Incubation Time: 8 h
Result: Restored cell viability reduced by thapsigargin-induced ER stress in a concentration-dependent manner.
Significantly increased viability at all tested concentrations.

Apoptosis Analysis

Cell Line: HIT-T15 hamster insulinoma cells
Concentration: 0.1 μM, 1 μM (co-treated with 0.3 μM thapsigargin)
Incubation Time: 8 h
Result: Reduced the apoptosis rate from 51.65% (thapsigargin alone) to 13.37% at 0.1 μM.
Reduced the apoptosis rate from 51.65% (thapsigargin alone) to 12.75% at 1 μM.

Western Blot Analysis

Cell Line: HIT-T15 hamster insulinoma cells
Concentration: 1 μM, 10 μM (co-treated with 1 μM thapsigargin)
Incubation Time: 6 h
Result: Attenuated thapsigargin-induced phosphorylation of JNK, ERK1/2, and p38 MAPK in a concentration-dependent manner.
Reduced phosphorylated JNK to 1.15 folds of control at 10 μM.
Reduced phosphorylated ERK1/2 to 1.19 folds of control at 10 μM.
Reduced phosphorylated p38 MAPK to 1.61 folds of control at 10 μM.
Reduced BiP protein to 0.769 folds of control at 10 μM.
Reduced CHOP protein to 0.789 folds of control at 10 μM.

Cell Viability Assay

Cell Line: siRNA-treated HIT-T15 hamster insulinoma cells
Concentration: 0.1 μM (co-treated with 1 μM thapsigargin, 48 h after siGPR119 transfection)
Incubation Time: 6 h
Result: Failed to significantly preserve viability in siGPR119-transfected cells.
Significantly rescued viability in control siRNA-transfected cells.
体内研究
(In Vivo)

DA-1241 (10-100 mg/kg; p.o.; 每日给药;连续 4 周) 可呈剂量依赖性地改善 MS-MASH 小鼠的血糖控制,并降低 MASH 相关的肝脏脂肪变性、炎症反应及甘油三酯水平,其降血糖功效在 30 mg/kg 时进入平台期。
DA-1241 (30-100 mg/kg/天;灌胃;每日;通过药物-饲料混合给药 8-12 周) 可减轻 DIO-MASH 小鼠中与 MASH 相关的肝脂肪变性、炎症、纤维化及肝损伤。
DA-1241 (1-10 mg/kg;灌胃;单次给药) 可剂量依赖性地抑制正常 ICR 小鼠餐后血浆甘油三酯的升高。
DA-1241 (120 mg/kg;每日给药;持续 12 周) 可通过促进 GLP-1 分泌以增强葡萄糖依赖性胰岛素释放,并抑制肝脏糖异生,改善高脂饮食诱导的糖尿病小鼠的血糖控制。
DA-1241 (100 mg/kg 每日给药,持续 4 周) 可通过 TFEB 介导的自噬诱导作用减轻 C57BL/6J 小鼠中由高脂饮食 (HFD) 诱导的非酒精性脂肪性肝病 (NAFLD),降低肝脏 TG 水平与 NAFLD 活动评分,并改善葡萄糖及胰岛素耐受性。
DA-1241 (0.3-30 mg/kg;灌胃;葡萄糖负荷前 30 分钟单次给药) 可剂量依赖性地降低正常 SD 大鼠的餐后血糖波动。
DA-1241 (3 mg/kg;灌胃;葡萄糖负荷前 30 分钟单次给药) 可通过提升血浆胰岛素及总 GLP-1 水平,降低野生型小鼠的餐后血糖波动。
DA-1241 (100 mg/kg/天;灌胃;每日;通过药物-饲料混合给药 10 周) 可改善血糖和甘油三酯控制,通过上调 PDX1 表达维持胰岛 β 细胞量,并在 HFD/STZ 诱导的糖尿病 ICR 小鼠中抑制内质网应激。

Animal Model: MS-MASH (5-week-old male; MASH model via 60% kcal fat high-fat diet)
Dosage: 10 mg/kg; 30 mg/kg; 100 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Inhibited fed blood glucose levels by 18.1%, 27.9%, and 27.5% at 10, 30, and 100 mg/kg respectively relative to vehicle control at week 4.\nLowered fasting plasma glucose, glycated hemoglobin, and fasting plasma triglyceride levels with 43.4 ± 3.7% inhibition vs. vehicle control.\nReduced the NAFLD Activity Score at all tested doses, with reduced hepatic steatosis and immune cell infiltration observed via histological analysis.
Animal Model: Lep^ob/Lep^ob (Ob) (male; MASH model via 10 weeks of Western diet feeding)
Dosage: 30 mg/kg/day; 100 mg/kg/day
Administration: p.o.; daily; 10 weeks; via drug-diet admixture
Result: Reduced the NAFLD Activity Score and liver fibrosis score, and increased plasma total GLP-1 levels significantly at 100 mg/kg/day relative to vehicle control.\nShowed trends toward improvement in NAFLD Activity Score, liver fibrosis score, and plasma total GLP-1 levels at 30 mg/kg/day.
Animal Model: C57BL/6 J STAM (8-week-old male; MASH model via neonatal streptozotocin injection plus high-fat diet feeding)
Dosage: 30 mg/kg
Administration: p.o.; daily; 4 weeks
Result: Reduced the NAFLD Activity Score significantly by alleviating steatosis, inflammation, and hepatocyte ballooning relative to vehicle control.\nReduced the hepatic Sirius red-positive fibrotic area fraction by 35.8%, though this did not reach statistical significance.
Animal Model: C57BL/6 J (male; MASH model via 27 weeks of Western diet feeding, pre-biopsied for fibrosis stage 1 or 2)
Dosage: 30 mg/kg/day; 100 mg/kg/day; 100 mg/kg/day (in combination with 150 mg/kg/day sitagliptin)
Administration: p.o.; daily; 8 weeks; via drug-diet admixture
Result: Reduced relative liver weight, hepatic cholesterol content, plasma ALT, AST, ALT/AST ratio, hepatic steatosis area, type I collagen area, and galectin-3-positive immune cell infiltration area at 30 mg/kg/day relative to vehicle control.\n
Further reduced relative liver weight, hepatic cholesterol content, plasma ALT/AST ratio, and decreased plasma free fatty acids, TIMP1, and type IV collagen levels at 100 mg/kg/day relative to vehicle control.\n
Produced greater improvements in combination with 150 mg/kg/day Sitagliptin (MS-M62474).\n
Downregulated 17 hepatic inflammatory signaling genes in DA-1241-treated groups via transcriptome analysis.
Animal Model: C57BL/6 J (male; MASH model via 30 weeks of Western diet feeding, pre-biopsied for fibrosis stage 1 or 2)
Dosage: 100 mg/kg/day; 100 mg/kg/day (in combination with 200 mg/kg/day evogliptin)
Administration: p.o.; daily; 12 weeks; via drug-diet admixture
Result: Reduced plasma ALT, AST, galectin-3-positive immune cell infiltration area, αSMA-positive stellate cell activation area, and plasma PINP, TIMP1, and type IV collagen levels at 100 mg/kg/day relative to vehicle control.\n
Produced greater improvements in combination with 200 mg/kg/day Evogliptin (MS-X11879).
Animal Model: ICR (7-week-old male; non-diseased, used for oral triglyceride tolerance testing)
Dosage: 1 mg/kg; 3 mg/kg; 10 mg/kg; 3 mg/kg (in combination with 30 mg/kg sitagliptin); 10 mg/kg (in combination with 30 mg/kg sitagliptin)
Administration: p.o.; single dose
Result: Reduced post-prandial plasma triglyceride levels dose-dependently, with 1.3%, 23.5%, and 31.2% reduction at 1, 3, and 10 mg/kg respectively.\n
Reduced the area under the plasma triglyceride curve (AUC0-6h) at 10 mg/kg.
Produced a greater reduction in peak plasma triglycerides in combination with 30 mg/kg sitagliptin than either agent alone, and significantly increased plasma total and active GLP-1 levels at 1.5 hours post-lipid challenge relative to vehicle control and monotherapy groups.
Animal Model: C57BL/6J (5-week-old male; acclimatized from 4 weeks old; high-fat diet-induced hyperglycaemia)
Dosage: 120 mg/kg
Administration: daily; 12 weeks
Result: Reduced fasting blood glucose levels significantly.\n
Improved oral glucose tolerance significantly.\n
Increased serum total GLP-1 levels during oral glucose tolerance test significantly. Increased serum insulin level 30 minutes after oral glucose challenge significantly.
Reduced hepatic triglyceride content significantly.\n
Reduced serum cholesterol levels significantly.\n
Attenuated hepatic protein expression of gluconeogenic enzymes glucose 6-phosphatase and phosphoenolpyruvate carboxykinase.
Showed no significant effects on body weight gain, food intake, intraperitoneal glucose tolerance, or insulin tolerance.
Animal Model: C57BL/6J mice
Dosage: 100 mg/kg per day
Administration: daily; 4 weeks
Result: Reduced body weight in HFD-fed mice.\n
Reduced area under the curve (AUC) of oral glucose tolerance test (OGTT) results, improving glucose tolerance.\n
Reduced AUC of insulin tolerance test (ITT) results, improving insulin sensitivity.\nSignificantly reduced serum AST, ALT, and TG levels.\n
Reduced hepatic TG levels.\nReduced hepatic steatosis, lobular inflammation, hepatocellular ballooning, and NAFLD activity scores.\nIncreased the number of autophagic vesicles and lysosomes in liver tissue.\n
Elevated liver LC3II protein levels, decreased liver p62 protein levels.\n
Enhanced TFEB nuclear translocation in liver tissue.
Animal Model: Liver-specific Tfeb knockout (L-Tfeb KO) mice (male, 5-6 weeks old); TFEB wild-type (WT) littermate mice (male, 5-6 weeks old)
Dosage: 100 mg/kg per day
Administration: daily; 4 weeks
Result: In TFEB WT HFD-fed mice: Reduced body weight.\nReduced OGTT AUC, improving glucose tolerance.\n
Reduced ITT AUC, improving insulin sensitivity.\nReduced serum AST, ALT, and TG levels.\nReduced hepatic TG levels.\nReduced hepatic steatosis, lobular inflammation, hepatocellular ballooning, and NAFLD activity scores.\n
Increased the number of autophagic vesicles and lysosomes in liver tissue.
Elevated liver LC3II protein levels, decreased liver p62 protein levels.
Animal Model: Sprague-Dawley (SD) (8-week-old male)
Dosage: 0.3, 3, 30 mg/kg
Administration: p.o.; single dose 30 minutes pre-glucose challenge
Result: Significantly and dose-dependently lowered blood glucose levels compared to vehicle control.\nReduced incremental glucose AUC (0-120 min) in a dose-dependent manner.
Animal Model: wild-type C57BL/6 (male); GPR119 knockout (KO) (male)
Dosage: 3 mg/kg
Administration: p.o.; single dose 30 minutes pre-glucose challenge
Result: Significantly reduced postprandial blood glucose levels from 30 minutes post-challenge in wild-type mice.
Did not significantly increase active GLP-1 levels in wild-type mice.
Animal Model: ICR (10-week-old male; HFD/STZ-induced diabetic)
Dosage: 100 mg/kg/day
Administration: p.o.; daily; 10 weeks via drug-diet admixture
Result: Significantly lowered fed and fasted blood glucose levels compared to diabetic vehicle control.\n
Reduced plasma triglyceride levels to 329.4 mg/dl.\n
Reduced liver triglyceride contents compared to diabetic vehicle control.\n
Significantly restored the PDX1-positive islet area from 32.98% to 53.72%.\n
Increased the insulin-positive islet area compared to diabetic vehicle control.\n
Suppressed the glucagon-positive islet area from 20.19% to 7.13%.\n
Significantly reduced the BiP-positive islet area in diabetic mice compared to diabetic vehicle control.
性状 固体
颜色 White to off-white

化学信息

分子量 471.54
分子式 C25H31F2N5O2
CAS No. 1914136-10-9

储存&溶解度

储存方式
Powder -20°C 3 years
4°C 2 years
In solvent -80°C 6 months
-20°C 1 month
运输条件 Room temperature in continental US; may vary elsewhere.
溶液配制表

DMSO 中的溶解度 : 100 mg/mL (212.07 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)

可选溶剂浓度1 mg5 mg10 mg25 mg
DMSO1 mM2.1207 mL10.6036 mL21.2071 mL53.0178 mL
5 mM0.4241 mL2.1207 mL4.2414 mL10.6036 mL
10 mM0.2121 mL1.0604 mL2.1207 mL5.3018 mL
15 mM0.1414 mL0.7069 mL1.4138 mL3.5345 mL
20 mM0.1060 mL0.5302 mL1.0604 mL2.6509 mL
25 mM0.0848 mL0.4241 mL0.8483 mL2.1207 mL
30 mM0.0707 mL0.3535 mL0.7069 mL1.7673 mL
40 mM0.0530 mL0.2651 mL0.5302 mL1.3254 mL
50 mM0.0424 mL0.2121 mL0.4241 mL1.0604 mL
60 mM0.0353 mL0.1767 mL0.3535 mL0.8836 mL
80 mM0.0265 mL0.1325 mL0.2651 mL0.6627 mL
100 mM0.0212 mL0.1060 mL0.2121 mL0.5302 mL

* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C, 6 months; -20°C, 1 month。-80°C储存时,请在6个月内使用,-20°C储存时,请在1个月内使用。

该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。

计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子摩尔量 (g/mol)
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
起始浓度(M)× 起始体积(L)= 最终浓度(M)× 最终体积(L)
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2
溶液体积 = 质量 ÷ 配液浓度
Volume (to add to vial) = Mass (in vial) ÷ Desired Reconstitution Concentration
÷
分子量计算器
Enter the chemical formula of the compound to calculate its molar mass and elemental composition
g/mol

体内实验配液计算器

动物实验计算换算器

请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:

比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。

母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。

体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清

以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。

方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系客服为您提供正确的澄清溶液配方)
+
+
+

计算结果:

工作液浓度: mg/ml;

DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,

体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。

1. 首先保证母液是澄清的;
           2. 一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。

开始您的科研之旅

20,0000+ 种高纯度分子化合物,专业靶点数据库,全程技术支持
让每一个实验数据都有坚实的分子基础